Tomohiko Ohta

The UPS: a promising target for breast cancer treatment (2008)

Sato, Ko, Rajendra, Eeson, Ohta, Tomohiko

Abstract During the past decade, progress in endocrine therapy and the use of trastuzumab has significantly contributed to the decline in breast cancer mortality for hormone receptor-positive and...

The ubiquitin E3 ligase activity of BRCA1 and its biological functions (2008)

Wu, Wenwen, Koike, Ayaka, Takeshita, Takashi, Ohta, Tomohiko

Abstract The basal-like breast cancer, a new category of breast cancer associated with poor prognosis and possibly unique chemosensitivity, is a current topic in the breast cancer field. Evidence...

Stem-Loop Binding Protein, the Protein That Binds the 3′ End of Histone mRNA, Is Cell Cycle Regulated by Both Translational and Posttranslational Mechanisms

Whitfield, Michael L., Zheng, Lian-Xing, Baldwin, Amy, Ohta, Tomohiko, Hurt, Myra M., Marzluff, William F.

The expression of the replication-dependent histone mRNAs is tightly regulated during the cell cycle. As cells progress from G1 to S phase, histone mRNA levels increase 35-fold, and they decrease...

The CUL1 C-Terminal Sequence and ROC1 Are Required for Efficient Nuclear Accumulation, NEDD8 Modification, and Ubiquitin Ligase Activity of CUL1

Furukawa, Manabu, Zhang, Yanping, McCarville, Joseph, Ohta, Tomohiko, Xiong, Yue

Members of the cullin and RING finger ROC protein families form heterodimeric complexes to constitute a potentially large number of distinct E3 ubiquitin ligases. We report here that the highly...

Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex

Brzovic, Peter S., Keeffe, Jennifer R., Nishikawa, Hiroyuki, Miyamoto, Keiko, Fox, David, Fukuda, Mamoru, ...

BRCA1 is a breast and ovarian cancer tumor suppressor protein that associates with BARD1 to form a RING/RING heterodimer. The BRCA1/BARD1 RING complex functions as an ubiquitin (Ub) ligase with...

Stem-Loop Binding Protein, the Protein That Binds the 3′ End of Histone mRNA, Is Cell Cycle Regulated by Both Translational and Posttranslational Mechanisms

Whitfield, Michael L., Zheng, Lian-Xing, Baldwin, Amy, Ohta, Tomohiko, Hurt, Myra M., Marzluff, William F.

The expression of the replication-dependent histone mRNAs is tightly regulated during the cell cycle. As cells progress from G1 to S phase, histone mRNA levels increase 35-fold, and they decrease...

The CUL1 C-Terminal Sequence and ROC1 Are Required for Efficient Nuclear Accumulation, NEDD8 Modification, and Ubiquitin Ligase Activity of CUL1

Furukawa, Manabu, Zhang, Yanping, McCarville, Joseph, Ohta, Tomohiko, Xiong, Yue

Members of the cullin and RING finger ROC protein families form heterodimeric complexes to constitute a potentially large number of distinct E3 ubiquitin ligases. We report here that the highly...

Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex

Brzovic, Peter S., Keeffe, Jennifer R., Nishikawa, Hiroyuki, Miyamoto, Keiko, Fox, David, Fukuda, Mamoru, ...

BRCA1 is a breast and ovarian cancer tumor suppressor protein that associates with BARD1 to form a RING/RING heterodimer. The BRCA1/BARD1 RING complex functions as an ubiquitin (Ub) ligase with...

Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase ‘Synoviolin'

Yamasaki, Satoshi, Yagishita, Naoko, Sasaki, Takeshi, Nakazawa, Minako, Kato, Yukihiro, Yamadera, Tadayuki, ...

Synoviolin, also called HRD1, is an E3 ubiquitin ligase and is implicated in endoplasmic reticulum -associated degradation. In mammals, Synoviolin plays crucial roles in various physiological and...

The ubiquitin E3 ligase activity of BRCA1 and its biological functions

Wu, Wenwen, Koike, Ayaka, Takeshita, Takashi, Ohta, Tomohiko

The basal-like breast cancer, a new category of breast cancer associated with poor prognosis and possibly unique chemosensitivity, is a current topic in the breast cancer field. Evidence from...

The UPS: a promising target for breast cancer treatment

Sato, Ko, Rajendra, Eeson, Ohta, Tomohiko

During the past decade, progress in endocrine therapy and the use of trastuzumab has significantly contributed to the decline in breast cancer mortality for hormone receptor-positive and ERBB2...